Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of TheraSphere® for the Treatment of Unresectable Hepatocellular Carcinoma

NCT00039078 is registered in ClinicalTrials.gov with Allan Tsung as lead sponsor.

NCT NCT00039078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00039078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of TheraSphere® for the Treatment of Unresectable Hepatocellular Carcinoma
Lead sponsor
Allan Tsung
Phase
Phase 2
Overall status
Withdrawn
Start date
August 31, 2000
Completion date
August 31, 2000
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer